Anhui Anke Biotechnology (Group) Co., Ltd. (SHE:300009)

Market Cap	16.70B
Revenue (ttm)	2.53B
Net Income (ttm)	657.33M
Shares Out	1.67B
EPS (ttm)	0.39
PE Ratio	25.46
Forward PE	n/a
Dividend	0.30 (3.00%)
Ex-Dividend Date	May 23, 2025

Volume	19,718,920
Average Volume	39,784,809
Open	10.03
Previous Close	10.09
Day's Range	9.93 - 10.65
52-Week Range	7.38 - 13.06
Beta	0.46
RSI	35.83
Earnings Date	Oct 24, 2025

About SHE:300009

Anhui Anke Biotechnology (Group) Co., Ltd. engages in the biopharmaceutical industry in China and internationally. The company offers human growth hormone for injection under the Ansomone name; and recombinant human interferon alpha 2b lyophilized powder, liquid, and prefilled syringe for injection, as well as recombinant human interferon alpha 2b cream, eye drop, and suppository under the Anterferon name. It provides anti-sperm antibody, semen leukocyte peroxidase staining, one-time semen processing, sperm hypo-osmotic staining, sperm life det...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 2,647
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300009

Financial Performance

In 2024, SHE:300009's revenue was 2.54 billion, a decrease of -11.51% compared to the previous year's 2.87 billion. Earnings were 706.95 million, a decrease of -16.56%.